CD19 and neoplasm: It is notable that using either the 4-1BB or CD28 costimulatory domain in the context of the CD28 hinge and transmembrane domain resulted in CAR-Ts that had equivalent anti-tumor activity in an in vivo model of a CD19-low expressing leukemia.